- Home
- DATS vs CLRB Comparison
DATS vs CLRB Comparison
Compare DATS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- CLRB
- Stock Information
- Founded
- DATS 2014
- CLRB 2002
- Country
- DATS United States
- CLRB United States
- Employees
- DATS N/A
- CLRB N/A
- Industry
- DATS Computer Software: Prepackaged Software
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- CLRB Health Care
- Exchange
- DATS Nasdaq
- CLRB Nasdaq
- Market Cap
- DATS 10.9M
- CLRB 12.6M
- IPO Year
- DATS 2021
- CLRB N/A
- Fundamental
- Price
- DATS $2.57
- CLRB $0.31
- Analyst Decision
- DATS
- CLRB Hold
- Analyst Count
- DATS 0
- CLRB 1
- Target Price
- DATS N/A
- CLRB N/A
- AVG Volume (30 Days)
- DATS 924.7K
- CLRB 619.5K
- Earning Date
- DATS 05-13-2025
- CLRB 05-13-2025
- Dividend Yield
- DATS N/A
- CLRB N/A
- EPS Growth
- DATS N/A
- CLRB N/A
- EPS
- DATS N/A
- CLRB N/A
- Revenue
- DATS $436.00
- CLRB N/A
- Revenue This Year
- DATS N/A
- CLRB N/A
- Revenue Next Year
- DATS N/A
- CLRB N/A
- P/E Ratio
- DATS N/A
- CLRB N/A
- Revenue Growth
- DATS N/A
- CLRB N/A
- 52 Week Low
- DATS $1.01
- CLRB $0.22
- 52 Week High
- DATS $9.34
- CLRB $3.51
- Technical
- Relative Strength Index (RSI)
- DATS 48.61
- CLRB 53.10
- Support Level
- DATS $2.12
- CLRB $0.23
- Resistance Level
- DATS $2.73
- CLRB $0.32
- Average True Range (ATR)
- DATS 0.24
- CLRB 0.03
- MACD
- DATS -0.03
- CLRB 0.00
- Stochastic Oscillator
- DATS 44.79
- CLRB 90.33
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.